stockgist
HomeTop MoversCompaniesConcepts

Market

  • Top Movers
  • Companies
  • Concepts

SEC Filings

  • AI Filing Analysis
  • Financial Reports
  • Current Reports
  • IPO Filings

Ownership

  • Institutional Holdings
  • Insider Trading

About

  • Data updates every 5 min
  • SEC EDGAR Source
© 2025–2026 StockGist|Information only, not investment advice
    1. Companies
    2. SBFMW
    stockgist
    HomeTop MoversCompaniesConcepts
    SBFMW logo

    Sunshine Biopharma, Inc.

    SBFMW
    NASDAQ
    Healthcare
    Drug Manufacturers - Specialty & Generic
    Pointe-Claire, QC, CA52 employeessunshinebiopharma.com
    $0.09
    +0.00(0.00%)

    Mkt Cap $417.5K

    $0.07
    $0.58

    52-Week Range

    At a Glance

    AI-generated

    Sunshine Biopharma reported revenue growth of 4.1% to $36.3M in FY2025, with gross profit rising 14.9% and gross margin expanding to 33.8%, while operating and net losses widened modestly amid ongoing investment in generic pharmaceutical operations.

    8-K
    Sunshine Biopharma, Inc. entered into an engagement agreement with Aegis Capital Corp. on March 6, 2026. The agreement is filed as Exhibit 99.1 with the 8-K filing dated March 9, 2026.

    $417.5K

    Market Cap

    $268M

    Revenue

    -$43M

    Net Income

    Employees52
    Fundamentals

    How The Business Makes Money

    Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.

    Industry Drug Manufacturers - Specialty & Generic
    Activity

    What Changed Recently

    Management Change
    Feb 4, 2026

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 5

    Other Event
    Mar 8, 2026

    Other Events. On March 6, 2026, Sunshine Biopharma Inc. (the “Company”) entered into an engagement agreement with Aegis Capital Corp. (“Aegis”) pursuant to whic

    Shareholder Vote
    Feb 19, 2026

    Submission of Matters to a Vote of Security Holders. On February 18, 2026, Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockh

    Company Profile
    CIK0001402328
    ISINUS8677815024
    CUSIP867781502
    Phone514 426 6161
    Address6500 Trans-Canada Highway, Pointe-Claire, QC, H9R 0A5, CA
    SEC EDGAR

    Market

    • Top Movers
    • Companies
    • Concepts

    SEC Filings

    • AI Filing Analysis
    • Financial Reports
    • Current Reports
    • IPO Filings

    Ownership

    • Institutional Holdings
    • Insider Trading

    About

    • Data updates every 5 min
    • SEC EDGAR Source
    © 2025–2026 StockGist|Information only, not investment advice